Melissa M. Yoon
General Counsel at Ambry Genetics Corp.
Profile
Melissa M.
Yoon is currently the General Counsel at Ambry Genetics Corp.
She previously worked as a Secretary at Akcea Therapeutics, Inc.
Melissa M. Yoon active positions
| Companies | Position | Start |
|---|---|---|
Ambry Genetics Corp.
 Ambry Genetics Corp. Miscellaneous Commercial ServicesCommercial Services Ambry Genetics Corp. provides clinical genetic diagnostics and genetics software solutions. Its services include clinical diagnostics tests, forms, billing, order kits, patient resources about cancer, cardiology, billing information and research and collaboration services. The company was founded by Charles L.M. Dunlop and James Dunlop in 1999 and is headquartered in Aliso Viejo, CA. | General Counsel | - |
Former positions of Melissa M. Yoon
| Companies | Position | End |
|---|---|---|
| AKCEA THERAPEUTICS, INC. | Corporate Secretary | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Ambry Genetics Corp.
Ambry Genetics Corp. Miscellaneous Commercial ServicesCommercial Services Ambry Genetics Corp. provides clinical genetic diagnostics and genetics software solutions. Its services include clinical diagnostics tests, forms, billing, order kits, patient resources about cancer, cardiology, billing information and research and collaboration services. The company was founded by Charles L.M. Dunlop and James Dunlop in 1999 and is headquartered in Aliso Viejo, CA. | Commercial Services |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Melissa M. Yoon
